Real-world data highlight transformational outcomes seen with Lucentis®

Novartis has reported that new data with the eye drug Lucentis® (ranibizumab), first licensed in June 2006, is highlighted in a total of 209 abstracts at the 2013 Association for Research in Vision and Ophthalmology (ARVO) annual meeting this week.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Source Type: news